Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EQL Pharma AB's gross profit for the
three
months ended in Jun. 2026 was kr17.8 Mil. EQL Pharma AB's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was kr134.5 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. EQL Pharma AB's gross profit for the
three
months ended in Jun. 2026 was kr17.8 Mil. EQL Pharma AB's Revenue for the
three
months ended in Jun. 2026 was kr106.9 Mil. Therefore, EQL Pharma AB's Gross Margin % for the quarter that ended in Jun. 2026 was 16.68%.
EQL Pharma AB had a gross margin of 16.68% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of EQL Pharma AB was 69.93%. The lowest was 23.36%. And the median was 44.06%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
EQL Pharma AB had a gross margin of 16.68% for the quarter that ended in Jun. 2026 => No sustainable competitive advantage
EQL Pharma AB Gross Profit Related Terms
EQL Pharma AB Gross Profit Historical Data
* Premium members only.
The historical data trend for EQL Pharma AB's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EQL Pharma AB Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's Gross Profit distribution charts can be found below:
* The bar in red indicates where EQL Pharma AB's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr134.5 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
EQL Pharma AB (OSTO:EQL) has a Gross Profit of kr134.5 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on EQL Pharma AB and its competitors.
Is EQL Pharma AB's Gross Profit too high?
EQL Pharma AB's current Gross Profit is kr134.5 Mil. Overall, EQL Pharma AB has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does EQL Pharma AB's Gross Profit compare to ZTS?
EQL Pharma AB's Gross Profit of kr134.5 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on EQL Pharma AB and its competitors. EQL Pharma AB's current Gross Profit is kr134.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EQL Pharma AB stock overvalued right now?
EQL Pharma AB (OSTO:EQL) has a current Gross Profit of kr134.5 Mil. The current Gross Profit is kr134.5 Mil. EQL Pharma AB's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current Gross Profit is kr134.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.
38GF Score
Get the complete analysis for OSTO:EQL
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EQL has been successfully added to your 
